ChosenMed Technology

About ChosenMed Technology

Founded in 2017, ChosenMed Technology is a provider of oncology products and services based on next-generation sequencing (NGS) and bioinformatics data analysis. The company, headquartered in Beijing, China, focuses on precision medicine solutions across the entire cancer care continuum. Its services include early tumor screening, diagnosis, dynamic monitoring, medication guidance, and prognostic evaluation.

The company's business model revolves around developing and commercializing diagnostic products for the liquid biopsy field. ChosenMed collaborates with hospitals and pharmaceutical companies, participating in projects like the "China Cancer Genome Atlas Project" to identify biomarkers specific to the Chinese population and support anti-cancer drug development. It provides partner hospitals with comprehensive, automated high-throughput sequencing solutions, from sample testing to report generation. ChosenMed's product portfolio includes the Chosen series of companion diagnostic and early screening tests for various cancers and an information platform, ChosenMedInfo, which offers tools for clinical data collection, knowledge mining, and data analysis.

The founder, Dr. Qiming Zhou, serves as the company's chairman. He earned his Ph.D. from the Institute of Microbiology at the Chinese Academy of Sciences and has prior experience as a department director at Bio-chip and an associate researcher at the Chinese Academy of Sciences, specializing in genomics. ChosenMed has secured significant funding through multiple rounds, with investors including Yijing Capital, Hunan High-Tech Investment Group, and Shanghai Alliance Investment.